Mechanisms involved in degradation of activated thyrosine kinase mutants induced by anti-cancer drugs and its clinical application
| Project/Area Number |
24790966
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
NAGAO Toshikage 東京医科歯科大学, 医学部附属病院, 助教 (10622798)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 造血器腫瘍 / Jak2-V617F / MYD88 |
|---|
| Research Abstract |
To explore the mechanisms that are involved in the enhanced cell survival and proliferation induced by the activated Jak2 mutant Jak2-V617F, known to be deeply linked to pathogenesis of some myeloid malignancies, we examined newly established Jak2-V617 bearing leukemic cell line PVTL-1. Consequently, not only Jak2-V617F but also the Src family kinase Lyn was constitutively activated and phosphorylated various kinds of intracellular signaling molecules. Additionally, it was suggested that apoptosis may be suppressed in PVTL-1 cells through inactivation of GSK3 by Lyn as well as Jak2-V617F and that activation of the mTOR/p70S6K/4EBP1 pathway may mediate proliferation signaling from Jak2-V617F and Lyn. On the other hand, we identified a novel mutation of TLRs/IL-1R associated adaptor protein MYD88, MYD88-L265-RPP, from the clinical sample of a Waldenstrom's macroglobulinemia case. Cells expressing this mutant showed significant activation of the NF-kB pathway.
|
Report
(3 results)
Research Products
(14 results)
